Kamari Pharma develops TRPV3 inhibitors that repair skin damage associated with rare dermatological diseases and chronic itch. Their technology targets the TRPV3 channel, a key regulator of skin homeostasis, to address significant gaps in treatment options for patients.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GFounders
Product
Problem
Many rare dermatological diseases and conditions causing chronic itch lack effective treatment options, leaving patients with limited relief from skin damage and discomfort. Current therapies often fail to address the underlying causes of these conditions, resulting in persistent symptoms and reduced quality of life.
Solution
Kamari Pharma is developing TRPV3 inhibitors designed to repair skin damage and alleviate chronic itch associated with rare dermatological diseases. Their technology targets the TRPV3 channel, a key regulator of skin homeostasis, to restore balance and function within the skin. By modulating TRPV3 activity, Kamari Pharma aims to provide innovative treatments that address the root causes of these conditions, offering patients improved symptom management and enhanced skin health. The inhibitors represent a novel approach to patient care, offering a potential breakthrough in the treatment of unmet needs in rare skin diseases.
Target Audience
The primary target audience includes patients suffering from rare dermatological diseases and chronic itch, as well as dermatologists and other healthcare professionals seeking innovative treatment options for these conditions.
Features
- TRPV3 inhibitors designed to modulate the activity of the TRPV3 channel.
- Targeted approach to restore skin homeostasis and repair skin damage.
- Potential to alleviate chronic itch associated with various dermatological conditions.
- Focus on addressing unmet needs in the treatment of rare skin diseases.